/ Print /

amcp nexus 2017

Payers struggle to keep up with high rate of FDA drug approvalsFDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Payers can predict budget implications of high-cost drugs in the pipelineA University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Meeting the ‘status quo’ with CMS Star Ratings equals regressionCMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
Payers need access to pre-approval drug informationPre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
Survey: How payers use nonpayer generated data to make formulary decisionsExternal, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Highly specific indications dominate cancer drug pipelineRecent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
Monetary benefits from value-based diabetes plans take timeValue-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
Incremental clinical advances for Duchenne Muscular DystrophyJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.
Rapid oncology innovation raises management challenges for payersOncology is a complex and rapidly-evolving management challenge for payers.